The primary uses of periciazine include in the short-term treatment of severe anxiety or tension and in the maintenance treatment of psychotic disorders such as schizophrenia. There is insufficient evidence to determine whether periciazine is more or less effective than other antipsychotics.[2] A 2014 systematic review compared periciazine with typical antipsychotics for schizophrenia:
Periciazine has also been studied in the treatment of opioid dependence.[5]
The final step in the synthesis involves the alkylation of 3-(2-cyanophenothiazin-10-yl)propyl 4-methylbenzenesulfonate, CID:134990672 (1) with 4-Piperidinol [5382-16-1] (2) giving Periciazine (3).
References
^Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ a b c d"NEULACTIL PRODUCT INFORMATION" (PDF). TGA eBusiness Services. sanofi-aventis australia pty ltd. 13 September 2011. Retrieved 2 November 2013.
^Pericyazine. The Royal Pharmaceutical Society of Great Britain. 23 September 2011. Retrieved 2 November 2013. {{cite book}}: |work= ignored (help)
^ a bMatar HE, Almerie MQ, Makhoul S, Xia J, Humphreys P (May 2014). "Pericyazine for schizophrenia". The Cochrane Database of Systematic Reviews. 2014 (5): CD007479. doi:10.1002/14651858.CD007479.pub2. PMC 11023599. PMID 24825770.
^Sivolap IuP, Savchenkov VA (1999). "[The use of neuroleptics in treating opiate dependence]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova (in Russian). 99 (6): 29–34. PMID 10441864.
^ a b"Approximate relative frequency (not intensity) of common adverse effects of antipsychotics (Table 8.21) [NB1]". eTherapeutic Guidelines complete. Therapeutic Guidelines Limited. February 2013. Retrieved 2 November 2013.[permanent dead link]
^FR1212031 idem Robert Jacques Georges, Jacob Robert Michel, U.S. patent 3,075,976 (1963 to Rhone Poulenc Sa).
External links
Neulactil - Summary of Product Characteristics from the electronic Medicines Compendium